Recruiting

SSGJ-707 for Advanced Gynecologic Cancer

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to evaluate the effectiveness and safety of SSGJ-707 in women with advanced gynecologic cancer by assessing the response rate and monitoring for any adverse effects.

What is being tested

SSGJ-707

+ carboplatin

+ paclitaxel

Drug
Who is being recruted

Urogenital Diseases+9

+ Genital Diseases

+ Female Urogenital Diseases and Pregnancy Complications

From 18 to 75 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: October 2024
See protocol details

Summary

Principal SponsorSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Study ContactZHOU, PhD
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: October 10, 2024

Actual date on which the first participant was enrolled.

This clinical trial is exploring a new treatment for women with advanced or recurring endometrial cancer and ovarian cancer that does not respond to standard platinum-based treatments. The study focuses on a drug named SSGJ-707, which is being tested in combination with existing chemotherapy. The goal is to determine whether this combination is safe and effective at fighting these types of cancers. This trial is significant as it seeks to offer new hope to patients with these challenging conditions by potentially improving their treatment options. Participants in this study will receive the drug SSGJ-707 along with standard chemotherapy. Researchers will monitor the patients closely to assess how the body tolerates the treatment and to evaluate its impact on the cancer. The study is designed to check the safety of the drug and its ability to reduce tumor growth. By examining these factors, the trial aims to gather valuable information that could lead to more effective treatments for patients with these specific types of cancer.

Official TitleA Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 in Advanced Gynecologic Cancer Patients
NCT06522828
Principal SponsorSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Study ContactZHOU, PhD
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

80 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 75 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleGenital Neoplasms, FemaleNeoplasmsNeoplasms by SiteUrogenital NeoplasmsUterine DiseasesUterine NeoplasmsEndometrial NeoplasmsFemale Urogenital Diseases

Criteria

5 inclusion criteria required to participate
Age:18-75 years old
Advanced endometrial cancer and platinum-resistant ovarian cancer
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Expected survival >=12 weeks.
Show More Criteria
5 exclusion criteria prevent from participating
Known uncontrolled or symptomatic central nervous system metastatic disease.
Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria [NCI CTCAE] v.5.0).
Inadequate organ or bone marrow function.
Pregnant or breast-feeding woman.
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

4 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental

Group II

Experimental

Group III

Experimental

Group IV

Experimental

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Chongqing Cancer Hospital

Chongqing, ChinaOpen Chongqing Cancer Hospital in Google Maps
Recruiting
One Study Center